MRAS抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: Human fetal brain tissue lysate, Primary antibody: P05763(MRAS Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

MRAS (Muscle RAS oncogene homolog) is a member of the RAS oncogene family, which includes well-studied proteins like HRAS, KRAS, and NRAS. It plays a role in regulating cell proliferation, differentiation, and survival through the RAS-MAPK signaling pathway. Unlike its more characterized relatives, MRAS has unique features, including preferential activation of specific downstream effectors like ROCK1/2. and is often co-amplified with the tumor suppressor gene PPP1R13B in cancers. Dysregulation of MRAS is implicated in various cancers, including lung, thyroid, and colorectal carcinomas, as well as cardiovascular diseases and Noonan syndrome.

Antibodies targeting MRAS are primarily used as research tools to study its expression, localization, and signaling mechanisms. They enable detection of MRAS in techniques like Western blotting, immunohistochemistry, and immunofluorescence. Therapeutic development of MRAS-specific antibodies remains challenging due to the historically undruggable nature of RAS proteins. However, advances in epitope-specific targeting, nanobodies, or bispecific antibodies have shown preclinical potential. Recent efforts also explore combining MRAS inhibitors with immunotherapies or targeted therapies to overcome resistance. Despite progress, MRAS antibody applications in diagnostics or therapeutics are still emerging, requiring further validation of their specificity and efficacy in clinical contexts.